Heinrich, Felix http://orcid.org/0009-0007-0981-6486
Cordts, Isabell http://orcid.org/0000-0002-2078-1997
Günther, René http://orcid.org/0000-0003-0329-5644
Stolte, Benjamin http://orcid.org/0000-0002-2774-067X
Zeller, Daniel http://orcid.org/0000-0003-3393-5657
Schröter, Carsten
Weyen, Ute
Regensburger, Martin http://orcid.org/0000-0002-2172-7386
Wolf, Joachim
Schneider, Ilka http://orcid.org/0000-0002-7109-2542
Hermann, Andreas http://orcid.org/0000-0002-7364-7791
Metelmann, Moritz http://orcid.org/0000-0002-8670-6148
Kohl, Zacharias http://orcid.org/0000-0002-4147-8866
Linker, Ralf A. http://orcid.org/0000-0002-8740-3106
Koch, Jan Christoph http://orcid.org/0000-0002-3778-0683
Radelfahr, Florentine http://orcid.org/0000-0003-2805-4652
Schönfelder, Erik
Gardt, Pavel
Mohajer-Peseschkian, Tara
Osmanovic, Alma http://orcid.org/0000-0002-6012-8423
Klopstock, Thomas
Dorst, Johannes http://orcid.org/0000-0001-6352-0909
Ludolph, Albert C. http://orcid.org/0000-0002-5401-0904
Schöffski, Oliver http://orcid.org/0000-0002-0048-0302
Boentert, Matthias http://orcid.org/0000-0001-6133-1397
Hagenacker, Tim http://orcid.org/0000-0002-3631-3450
Deschauer, Marcus http://orcid.org/0000-0001-6116-6790
Lingor, Paul http://orcid.org/0000-0001-9362-7096
Petri, Susanne http://orcid.org/0000-0002-9783-8584
Schreiber-Katz, Olivia http://orcid.org/0000-0001-5621-4487
Funding for this research was provided by:
Deutsche Gesellschaft für Muskelkranke
Medizinische Hochschule Hannover (MHH)
Article History
Received: 19 March 2023
Revised: 6 June 2023
Accepted: 7 June 2023
First Online: 25 June 2023
Declarations
:
: F. Heinrich reports no disclosures relevant to the manuscript. I. Cordts reports no disclosures relevant to the manuscript. R. Günther reports no disclosures relevant to the manuscript. B. Stolte received speaker honoraria from Biogen without relation to ALS. D. Zeller received compensation for participation on an advisory board of Biogen, as well as for consultancy work from Novartis. C. Schröter reports no disclosures relevant to the manuscript. U. Weyen received compensation for activities with Merz and Desitin. M. Regensburger reports no disclosures relevant to the manuscript. J. Wolf reports no disclosures relevant to the manuscript. I. Schneider received personal/speaker fees from Sanofi-Genzyme, Biogen, and from the German Neuromuscular Society “Deutsche Gesellschaft fuer Muskelkranke” (DGM e.V.) without relation to ALS. A. Hermann received compensation for consultant work for Biogen, Desitin, and Roche. Additionally, A. Hermann received research funding from BMBF, GBA-Innovations Fund, Helmholtz Gesellschaft, NOMIS-Foundation, and “Hermann und Lilly-Schilling Stiftung fuer medizinische Forschung” im Stifterverband. M. Metelmann reports no disclosures relevant to the manuscript. Z. Kohl reports no disclosures relevant to the manuscript. R.A. Linker received compensation for activities with Biogen, Celgene, Merck, Novartis, and Roche, as well as research support from DFG, Else-Kroener-Fresenius Stiftung, Biogen, and Novartis. J.C. Koch received personal fees from Biogen, Roche, Avexis, Abbvie, and Ipsen, and funding by the “Deutsche Gesellschaft fuer Muskelkranke” (DGM e.V.) outside of the submitted work. F. Radelfahr reports no disclosures relevant to the manuscript. P. Schischlevskij reports no disclosures relevant to the manuscript. E. Schönfelder reports no disclosures relevant to the manuscript. T. Mohajer-Peseschkian reports no disclosures relevant to the manuscript. A. Osmanovic received honoraria as a speaker/consultant from the German Neuromuscular Society “Deutsche Gesellschaft fuer Muskelkranke” (DGM e.V.), Biogen, and Impulze. T. Klopstock reports no disclosures relevant to the manuscript. J. Dorst reports no disclosures relevant to the manuscript. A.C. Ludolph received honoraria from Desitin, Novartis, Biogen, Roche, and the German Society of Neurology (Deutsche Gesellschaft fuer Neurologie e.V.). O.Schöffski reports no disclosures relevant to the manuscript. M. Boentert received honoraria from UCB Pharma, Desitin, Löwenstein Medical, Sanofi-Genzyme, and Biogen, as well as financial research support from Sanofi-Genzyme and Löwenstein Medical. T. Hagenacker received honoraria from Biogen, Roche, Novartis, and Alexion without relation to ALS, and received research funding from Biogen, AveXis, and Roche without relation to ALS. M. Deschauer received personal fees as a speaker/consultant from Biogen, Roche, Sanofi-Genzyme, and Alnylam Pharmaceuticals. P. Lingor received honoraria from ITF-Pharma and Desitin with relation to ALS. S. Petri received honoraria as speaker/consultant from Biogen GmbH, Roche, Novartis, Teva, Cytokinetics Inc., Desitin, Italfarmaco, Amylyx, and Zambon; and grants from DGM e.V, Federal Ministry of Education and Research, German Israeli Foundation for Scientific Research and Development, EU Joint Program for Neurodegenerative Disease Research. O. Schreiber-Katz received honoraria as a speaker/consultant and/or funding for travel expenses from the German Neuromuscular Society “Deutsche Gesellschaft fuer Muskelkranke” (DGM e.V.), Novartis, Biogen GmbH, Biermann Verlag GmbH, and MK + S—Medizin, Kommunikation & Service GmbH.
: The Ethics Board of Hannover Medical School approved the study (no. 7922_BO_K_2018, date: July and November 2018), as well as the local Ethics Boards of the individual MND Network centers.
: Written informed consent was obtained from all participants involved in the study and before study enrolment.